Antengene to Host Research and Development Day on November 15th and 17th, 2022 – QNT Press Release

[ad_1]

  • Virtual English Session:
    Tuesday, November 15 at 8:30am12:00 PM Eastern Time
    November 15 at 9:30pmNovember 16 at 1:00 AM Beijing Time
  • Hybrid Mandarin Session in Shanghai:
    Thursday, November 17 at 1:30pm5:30pm Beijing Time

SHANGHAI and HONG KONG, Oct. 26, 2022 /PRNewswire/ — Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, today announced that it will host its R&D Day for the investment community on November 15th (Virtual English Session) and November 17th (Hybrid Mandarin Session in Shanghai) since its inception to review Antengene’s R&D strategy and pipeline, the commercial launch of XPOVIO® (selinexor) underway in China and other markets in Asiaand other important company updates.

“We look forward to updating the investment community during Antengene’s R&D Day 2022,” said Dr. Jay MeiAntengene’s Founder, Chairman and CEO. “Over the last year, Antengene has successfully transitioned to an innovative commercial-stage global biopharmaceutical …

Full story available on Benzinga.com

[ad_2]

Source link